雅培公司利托那韦的专利布局及其对国内企业的启示  

Patents portfolio of Abbott's ritonavir and its enlightenment for domestic enterprises

作　　者：胡敬东[1] 卞志家[1] 杨秦[1] 张慧艳[1] 

机构地区：[1]国家知识产权局专利局专利审查协作北京中心医药生物部,北京100190

出　　处：《中国医药科学》2014年第16期147-151,190,共6页China Medicine And Pharmacy

摘　　要：本文通过综合运用STN、WPI和CNPAT数据库进行检索和分析,分析了作为利托那韦原研企业的雅培如何从化合物、药物制剂、合成方法、联合用药、化合物晶型、新用途和前药等几个方面在全球和中国构建有层次的专利保护网。同时还对中国申请人利托那韦的相关重点专利进行了分析,以期在对比之下探寻国内相关生产企业研发突破口。In this article, as the original researcher of ritonavir, how did Abbott construct gradational patent protection network in the world and China from several aspects , including compounds, pharmaceutical preparations, synthesis, combination therapies, polymorphism of compounds, new uses and prodrugs, was analyzed by combinational utilization of STN, WPI and CNPAT databases. Meanwhile, several important patents applied by Chinese applicants were also analyzed, in order to explore the breakthrough of R＆D for those related domestic enterprises by comparison.

关 键 词：利托那韦 专利 雅培 

分 类 号：R978.7[医药卫生—药品]